Cue Biopharma, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | FiledHerewith | Form | Exhibit | Filing Date | Registration/File No. |
| 3.1 · Amended and Restated Certificate of Incorporation, as amended · X | ||||||
| 4.1 | Form of Pre-Funded Warrant | 8-K | 4.1 | 4/15/2025 | 001-38327 | |
| 4.2 | Form of Common Stock Warrant | 8-K | 4.2 | 4/15/2025 | 001-38327 | |
| 10.1 | Cue Biopharma, Inc. 2025 Stock Incentive Plan | 8-K | 99.1 | 6/10/2025 | 001-38327 | |
| 10.2 | Second Amendment to the License Agreement, dated June 30, 2025, between Cue Biopharma, Inc. and MIL 40G, LLC | X | ||||
| 10.3# | Collaboration and License Agreement between the Registrant and Boehringer Ingelheim International GmbH dated April 10, 2025 | 10-Q | 10.2 | 5/12/2025 | 001-38327 | |
| 10.4# | Third Amendment to the Amended and Restated License Agreement with Albert Einstein College of Medicine dated April 10, 2025 | 10-Q | 10.3 | 5/12/2025 | 001-38327 | |
| 31.1 | Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, has been formatted in Inline XBRL. | X | ||||
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cue Biopharma, Inc. | ||
| Dated: August 12, 2025 | By: | /s/ Daniel R. Passeri |
|---|---|---|
| Daniel R. PasseriChief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.